Publication

Article

CURE

Winter 2007
Volume6
Issue 6

Senate Committee Approval Advances the Conquer Childhood Cancer Act

Senate passes the Conquer Childhood Cancer Act for research funding.

The Conquer Childhood Cancer Act, a bill that earmarks $150 million over five years for research into childhood cancers, passed its first hurdle on November 14 when a Senate committee approved it unanimously. The bill, sponsored by Senator Jack Reed (D-Rhode Island), has bi-partisan support. The next step will be to bring the legislation before the Senate for a vote.

Representative Deborah Pryce (R-Ohio), whose daughter died at age 9 of neuroblastoma, a rare brain cancer, introduced the companion bill in the House in early 2007. The bill has not yet made it out of committee.

The Conquer Childhood Cancer Act has been championed by several organizations, including CureSearch, a collaboration between the National Childhood Cancer Foundation and the Children’s Oncology Group. The legislation will expand biomedical research programs through the National Cancer Institute, establish a fellowship program to encourage researchers to focus on pediatric cancers, provide educational support for patients and their families, and set up a population-based national database to evaluate the incidence trends of childhood cancers and to enable genetic research to determine better prevention and treatment strategies.

The legislation comes at a time when research funding for childhood cancers has steadily decreased over the past five years, though it remains the top cause of death for children under 15.

Related Videos
Dr. Guru Sonpavde emphasized the importance of better understanding how genetic mutations influence the treatment of cancer care, particularly GU cancers.
Dr. Frederick L. Locke sat down with CURE® to discuss treatment with cema-cel in the ALPHA/ALPHA2 studies for relapsed/refractory large B-cell lymphoma.
Treatment with cemacabtagene ansegedleucel demonstrated responses in patients with relapsed or treatment-resistant large B-cell lymphoma.
Image of doctor with brown hair.
Image of man with black hair.
.Dr. Catherine Wu, chief of the Division of Stem Cell Transplantation and Cellular Therapies at Dana-Farber Cancer Institute, and institute member at the Broad Institute of MIT and Harvard, in Boston
Dr. Katy Beckermann discusses how a Fotivda and Opdivo combination for renal cell carcinoma compared with Fotivda alone based on patient feedback.
Dr. Catherine Wu is chief of the Division of Stem Cell Transplantation and Cellular Therapies at Dana-Farber Cancer Institute, and institute member at the Broad Institute of MIT and Harvard, in Boston, Massachusetts.
Dr. Alan Tan is the GU Oncology Lead at the Vanderbilt-Ingram Cancer Center in Nashville, Tennessee, as well as an associate professor in the Division of Hematology/Oncology at Vanderbilt University Medical Center and GU Executive Officer with the Alliance for Clinical Trials in Oncology.
Dr. Sattva S. Neelapu is a professor and deputy department chair in the Department of Lymphoma/Myeloma, Division of Cancer Medicine, at The University of Texas MD Anderson Cancer Center, in Houston, as well as a member of Graduate Faculty, Immunology Program, Graduate School of Biomedical Sciences, at The University of Texas Health Science Center, also located in Houston.